These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11043500)

  • 41. Transcardiac release of soluble adhesion molecules during coronary artery bypass grafting: effects of crystalloid and blood cardioplegia.
    Kalawski R; Majewski M; Kaszkowiak E; Wysocki H; Siminiak T
    Chest; 2003 May; 123(5):1355-60. PubMed ID: 12740247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon.
    Coffman JD; Cohen RA
    Clin Sci (Lond); 1994 Mar; 86(3):269-73. PubMed ID: 8156737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin.
    Edwards CM; Marshall JM; Pugh M
    Clin Sci (Lond); 1999 Jun; 96(6):577-88. PubMed ID: 10334963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma levels of tumor necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud's phenomenon.
    Cimminiello C; Arpaia G; Toschi V; Rossi F; Aloisio M; Motta A; Bonfardeci G
    Angiology; 1994 Dec; 45(12):1015-22. PubMed ID: 7985828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Raynaud's phenomenon in children].
    Quartier P
    Arch Pediatr; 2004 Jan; 11(1):74-7. PubMed ID: 14700771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of von Willebrand factor and fibrinogen plasma levels with primary Raynaud's phenomenon in male and female patients.
    Takáts AT; Shemirani AH; Zsóri KS; András C; Csiki Z
    Rheumatol Int; 2013 Apr; 33(4):1083-4. PubMed ID: 22108676
    [No Abstract]   [Full Text] [Related]  

  • 47. Endothelial expression of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 is suppressed by postbypass plasma containing increased soluble intercellular adhesion molecule 1 and vascular cell adhesion molecule 1.
    Vallely MP; Bannon PG; Hughes CF; Kritharides L
    J Thorac Cardiovasc Surg; 2002 Oct; 124(4):758-67. PubMed ID: 12324734
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Raynaud's phenomenon in Northern Sweden: a population-based nested case-control study.
    Stjernbrandt A; Pettersson H; Liljelind I; Nilsson T; Wahlström J
    Rheumatol Int; 2019 Feb; 39(2):265-275. PubMed ID: 30128730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis.
    Blann AD; McCollum CN
    Thromb Haemost; 1994 Jul; 72(1):151-4. PubMed ID: 7526483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Soluble intercellular adhesion molecule-1 and E-selectin as markers of disease activity and endothelial activation in juvenile idiopathic arthritis.
    Bloom BJ; Nelson SM; Eisenberg D; Alario AJ
    J Rheumatol; 2005 Feb; 32(2):366-72. PubMed ID: 15693101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macular capillary hemodynamic changes associated with Raynaud's phenomenon.
    Salmenson BD; Reisman J; Sinclair SH; Burge D
    Ophthalmology; 1992 Jun; 99(6):914-9. PubMed ID: 1630781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease].
    Yokota S; Kuriyama T; Takahashi Y; Mori M; Shike H; Ibe M; Mitsuda T; Aihara Y
    Ryumachi; 1994 Dec; 34(6):955-60. PubMed ID: 7863385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The associations between plasma levels of von Willebrand factor and fibrinogen with Raynaud's phenomenon in men and women.
    Fraenkel L; Tofler GH; Zhang Y; Silbershatz H; D'Agostino RB; Wilson PW; Felson DT
    Am J Med; 2000 May; 108(7):583-6. PubMed ID: 10806290
    [No Abstract]   [Full Text] [Related]  

  • 56. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease.
    Rajagopalan S; Pfenninger D; Kehrer C; Chakrabarti A; Somers E; Pavlic R; Mukherjee D; Brook R; D'Alecy LG; Kaplan MJ
    Arthritis Rheum; 2003 Jul; 48(7):1992-2000. PubMed ID: 12847693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report.
    Lip GY; Blann AD; Zarifis J; Beevers M; Lip PL; Beevers DG
    J Hypertens; 1995 Dec; 13(12 Pt 2):1674-8. PubMed ID: 8903631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Raynaud's phenomenon].
    Ratner GL; Slutsker GE
    Khirurgiia (Mosk); 1991 Jun; (6):36-40. PubMed ID: 1770734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon.
    Marasini B; Cugno M; Bassani C; Stanzani M; Bottasso B; Agostoni A
    Int J Microcirc Clin Exp; 1992 Nov; 11(4):375-82. PubMed ID: 1459797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis.
    De Caterina R; Basta G; Lazzerini G; Dell'Omo G; Petrucci R; Morale M; Carmassi F; Pedrinelli R
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2646-54. PubMed ID: 9409238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.